Internacional

Major drugmaker loses $27 billion in market value after failed trial

Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.

Por Redacción Sinergia Empresarial · 09 de julio de 2026 · 1 min
Major drugmaker loses $27 billion in market value after failed trial

Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.

Sinergia Empresarial continuará el seguimiento de esta información sobre major drugmaker loses $27 billion in market value after failed trial y ampliará la cobertura conforme se confirmen nuevos elementos relevantes para el ecosistema empresarial.